In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli.
The in vitro antibacterial activity of zidovudine alone and in combination with ciprofloxacin was investigated. Zidovudine showed a good activity against Escherichia coli and Salmonella (MIC range 0.5-8 micrograms/ml and 1.5-62 micrograms/ml respectively) isolated from biological samples of HIV-infected patients. These strains proved to be extremely susceptible to ciprofloxacin alone. The interaction between zidovudine and ciprofloxacin ranged from additive activity to indifference. No antagonism was observed: the FIC index for every combination resulted < or = 1.5. The addition of AZT 1 mg/l (clinically achievable plasma concentration after therapeutic doses of 1200 mg/day) did not affect the bactericidal activity of ciprofloxacin; on the contrary, in some cases we observed an increase of bactericidal effect of the quinolone. These data have to be considered in patients with AIDS who can be treated concomitantly with zidovudine and ciprofloxacin.
Mascellino
M T
MT
Institute of Infectious Diseases, University La Sapienza, Rome, Italy.
Iona
E
E
Iegri
F
F
De Gregoris
P
P
Farinelli
S
S
D002939:Ciprofloxacin / Q000494:pharmacology*; D004338:Drug Combinations; D004926:Escherichia coli / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012475:Salmonella / Q000187:drug effects*; D015215:Zidovudine / Q000494:pharmacology*
D004338:Drug Combinations; D015215:Zidovudine; D002939:Ciprofloxacin